Cargando…
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Pramlintide (Symlin(®)), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug Administration for use along with premeal insulin in patients with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are ei...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761191/ https://www.ncbi.nlm.nih.gov/pubmed/19920907 |